Taffic 30 mg (Bictegravir/Emtricitabine/Tenofovir Alafenamide)

Taffic 30 mg is a single-tablet, once-daily regimen for the treatment of HIV-1 infection. It combines three potent antiretroviral agents: Bictegravir (an integrase strand transfer inhibitor), Emtricitabine, and Tenofovir alafenamide (both nucleoside/nucleotide reverse transcriptase inhibitors). This formulation offers strong viral suppression, excellent tolerability, and minimal side effects, making it a preferred option for both treatment-naïve and experienced patients.

Key Ingredients & Their Role:

• Bictegravir (30 mg): Blocks integrase enzyme, preventing viral DNA from integrating into human DNA.

• Emtricitabine (200 mg): Inhibits reverse transcriptase enzyme, stopping HIV replication.

• Tenofovir Alafenamide (25 mg): A newer generation tenofovir with lower kidney and bone toxicity.

Uses of Taffic 30 mg:

• First-line treatment of HIV-1 infection in adults and adolescents (≥25 kg).

• Helps reduce viral load to undetectable levels.

• Increases CD4+ T-cell count, supporting immune recovery.